VERAXA Biotech AG (NASDAQ: VRXA) has announced a significant expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 that cover its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company stated that previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
This patent expansion is crucial for VERAXA as it reinforces the company's long-term strategy to develop next-generation oncology therapeutics. The BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. This approach aims to reduce off-target effects and enhance therapeutic efficacy, addressing key challenges in current cancer treatments.
VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies that are intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate (ADC) and T-cell engager pipelines. These technologies are integral to the company's BiTAC-ADC and BiTAC-TCE platforms, which represent innovative formats in the field of bispecific antibodies.
The company's robust patent portfolio provides a competitive advantage by securing its technological innovations and potentially creating barriers to entry for competitors. With protection extending to 2047, VERAXA has a long runway to develop and commercialize its therapies without the immediate threat of patent expirations.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
For more information, visit the company's newsroom at http://ibn.fm/VRXA.
